BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1622179)

  • 1. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
    Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
    Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
    Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
    Kim MK; Nightingale C; Nicolau D
    Clin Pharmacokinet; 2003; 42(11):985-96. PubMed ID: 12908854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.
    Catchpole C; Andrews JM; Woodcock J; Wise R
    J Antimicrob Chemother; 1994 Jan; 33(1):103-10. PubMed ID: 8157550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
    Wise R; Kirkpatrick B; Ashby J; Griggs DJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):161-3. PubMed ID: 3105446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
    Hoogkamer JF; Kleinbloesem CH
    Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.
    Lubowski TJ; Nightingale CH; Sweeney K; Quintiliani R
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2758-60. PubMed ID: 1482143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
    Królicki A
    Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target site concentrations of ciprofloxacin after single intravenous and oral doses.
    Brunner M; Stabeta H; Möller JG; Schrolnberger C; Erovic B; Hollenstein U; Zeitlinger M; Eichler HG; Müller M
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3724-30. PubMed ID: 12435668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
    Heim-Duthoy K; Peltier G; Awni W
    Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
    Dan M; Weidekamm E; Sagiv R; Portmann R; Zakut H
    Antimicrob Agents Chemother; 1993 Feb; 37(2):293-6. PubMed ID: 8452360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
    Kees F; Naber KG; Schumacher H; Grobecker H
    Chemotherapy; 1988; 34(6):437-43. PubMed ID: 2468456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of fleroxacin into body tissues and fluids.
    Weidekamm E; Portmann R
    Am J Med; 1993 Mar; 94(3A):75S-80S. PubMed ID: 8452186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.